Julia Vlasova

Dr. Julia Vlasova


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Biomarker Insights
Verified
Journal Article
Open access
EME.V. Morozova
E.V. Morozova
JVJulia Vlasova
Julia Vlasova
MPM.V. Pryanishnikova
M.V. Pryanishnikova
KLKirill V. Lepik
Kirill V. Lepik
BAB.V. Afanasyev
B.V. Afanasyev
The introduction of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) has significantly increased survival rate and quality of life for patients with CML. Despite the high efficacy of imatinib, not all patients benefit from this treatment. Resistance to imatinib can develop from a number of mechanisms. One of the main reasons for treatment failure is a mutation in the BCR-ABL gene, which leads to therapy resistance and clonal evolution. Clearly, new treatment approaches are required for patients who are resistant to imatinib. However, mutated clones are usually susceptible to second-generation TKIs, such as nilotinib and dasatinib. The choice of the therapy depends on the type of mutation. A large trial program showed that dasatinib is effective in patients previously exposed to imatinib. However, for a minority of patients who experience treatment failure with TKI or progress to advanced-phase disease, allogeneic stem cell transplantation (allo-SCT) remains the therapeutic option. In spite of the high curative potential of allo-SCT, its high relapse rate still requires a feasible strategy of posttransplant treatment and prophylaxis. We report a case of a CML patient with primary resistance to first-line TKI therapy. The patient developed an undifferentiated blast crisis. Before dasatinib therapy, the patient was found to have an F317L mutation. He was successfully treated with dasatinib followed by allo-SCT. In the posttransplant period, preemptive dasatinib treatment was used to prevent disease relapse.

28 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LZLudmila Stepanovna Zubarovskaya
Ludmila Stepanovna Zubarovskaya
IMIvan Moiseev
Ivan Moiseev
MVMaria Dmidrievna Vladovskaya
Maria Dmidrievna Vladovskaya
NMNatalia Mikhailova
Natalia Mikhailova
EMElena Vladislavovna Morozova
Elena Vladislavovna Morozova
AKAlexander Kulagin
Alexander Kulagin
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).

1 May 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
IMIvan Moiseev
Ivan Moiseev
MDMikhail Drokov
Mikhail Drokov
YKYulia Kitaeva
Yulia Kitaeva
TRTatyana Rudakova
Tatyana Rudakova
MBMaria Barabanshchikova
Maria Barabanshchikova
AKAlexander Kulagin
Alexander Kulagin

22 May 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
APA. N. Petrova
A. N. Petrova
ELElza Lomaia
Elza Lomaia
EME. V. Morozova
E. V. Morozova
OSO. A. Shukhov
O. A. Shukhov
ECE. Yu. Chelysheva
E. Yu. Chelysheva
ЮВЮ. Ю. Власова
Ю. Ю. Власова
Background. The most common mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is point mutations in the BCR::ABL1 gene. Of particular importance is the T315I mutation, which causes insensitivity of leukemia cells to all ATp-competitive TKIs: imatinib and 2nd generation TKIs. Asciminib is the first drug of the STAMp inhibitor class that specifically interacts with the myristoyl-binding active site of the bCR::AbL1 molecule. In a phase I clinical trial, asciminib at a dose of 200 mg twice daily showed efficacy in the treatment of chronic phase (Cp) CML patients with T315I mutation. There are no data on the efficacy of asciminib therapy in patients with T315I mutation and additional chromosomal abnormalities (ACA) or advanced disease. The Russian part of the managed access program (MAp) has accumulated its own experience of using asciminib in CML patients with T315I mutation, including those with ACA and history of progression to the acceleration phase / blast crisis.Aim. To analyze the 3-year results of asciminib therapy as part of MAp in CML patients with T315I mutation.Materials and methods. In the MAp program to asciminib between October 2019 and January 2022 were included 26 CML patients with T315I mutation who were ineffective or intolerant to ATp-competitive TKIs therapy. Asciminib was administered at a dose of 200 mg twice daily. The efficacy and tolerability of asciminib therapy were assessed in accordance with national clinical guidelines and the 2020 European LeukemiaNet guidelines.At the time of asciminib therapy initiation, 19 (73 %) patients had Cp. four (15 %) patients had a history of acceleration phase (n = 3) and blast crisis (n = 1). four (15 %) patients had ACA immediately before the start of asciminib therapy, including a patient with a history of blast crisis. To analyze the asciminib therapy results, patients with a history of progression and / or ACA were combined into one group: 2Cp / Cp ACA+ (n = 7). More than half of patients (54 %) had previously received ponatinib.Results. The median duration of asciminib therapy was 31.6 (3.3–50) months. Of the 26 patients, 25 (96 %) are alive, one patient in the 2Cp / Cp ACA+ group died from progression of CML to myeloid blast crisis. In the total group, 14 patients (54 %) continued asciminib therapy, 12 (46 %) – discontinued treatment: most patients due to treatment failure (n = 9 (75 %)). In 3 patients (25 %), the reason for treatment discontinuation was allogeneic hematopoietic stem cell transplantation (all three achieved a complete cytogenetic response with asciminib therapy). No patients discontinued treatment due to toxicity. No new mutations, including asciminib resistance mutations, were detected during therapy.Progression-free survival and survival without therapy discontinuation at 3 years of follow-up in the total group were 92 and 58 %, respectively. when analyzing the Cp and 2Cp / Cp ACA+ groups, progression-free survival at 3 years of asciminib therapy was comparable. There was a trend toward decreased survival without therapy discontinuation in 2Cp / Cp ACA+ group (28 %) versus Cp group (63 %) (p = 0.0856).The probability of achieving a complete cytogenetic response / molecular response MR2 in all patients with T315I mutation by the 3rd year of asciminib treatment was 59 %, in the Cp and 2Cp / Cp ACA+ groups – 47 and 80 %, respectively; no significant difference were found between the groups (p = 0.08). The probability of achieving a major molecular response (MMR) in the total group by the 3rd year of asciminib treatment was 42 %; the probability of achieving MMR in the Cp and 2Cp / Cp ACA+ groups was 44 and 33 %, respectively; no significant difference were found between the groups (p = 0.6).In univariate analysis, significant favorable factors for achieving MMR were the molecular response at the start of asciminib therapy ≤10 %, the best molecular response in prior TKI therapy ≤1 %, and the absence of prior ponatinib treatment. In multivariate analysis, a history of ponatinib therapy was an independent significant factor for achieving MMR with asciminib therapy (p = 0.02; hazard ratio 12.08).Conclusion. The therapy results of patients in initially unfavorable 2Cp / Cp ACA+ group were comparable with Cp group in terms of both survival rates and probability of achieving responses. However, given the small number of patients in our cohort, the asciminib efficacy in patients with T315I+ CML with ACA and a history of progression requires further investigation. A factor that significantly reduced the probability of achieving MMR during asciminib treatment was a history of ponatinib therapy.

10 December 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
ATA. G. Turkina
A. G. Turkina
ELElza Lomaia
Elza Lomaia
EME. V. Morozova
E. V. Morozova
OVO. Yu. Vinogradova
O. Yu. Vinogradova
TMT. A. Mitina
T. A. Mitina
ЮВЮ. Ю. Власова
Ю. Ю. Власова
Background. The T315I mutation in BCR::ABL1 kinase domain determines the resistance of leukemia cells to tyrosine kinase inhibitors (TKIs) – imatinib and secondgeneration TKIs – in patients with chronic myeloid leukemia (CML). The impact of new T315I-targeted approaches on treatment outcomes is being actively studied.Aim. To evaluate the clinical characteristics and therapy approaches in chronic-phase CML patients with T315I mutation in clinical practice. An additional objective is to evaluate overall survival (OS) by considering the therapy provided.Materials and methods. The non-interventional retrospective multicenter study included 88 adult patients with chronic-phase CML and the T315I mutation identified between January 2015 and November 2023, with a follow-up period of ≥3 months from 6 hematology clinics in Russia. T315I-targeted therapy refers to TKIs registered in Russia with clinically proven efficacy against the T315I mutation – ponatinib and asciminib, as well as allogeneic hematopoietic stem cell transplantation.Results. The median time from diagnosis to T315I mutation detection was 47 (6–192) months. Patients with T315I received 1–6 lines of therapy; most often, the T315I mutation was detected after 2–3 lines of therapy. After T315I mutation detection, 68 (77 %) patients received T315I-targeted therapy. The probability of receiving T315I-targeted therapy was 51; 61; 74 and 84 % at 6; 12; 24 and 36 months after T315I mutation detection, respectively, and was statistically significantly higher in patients with a detected mutation in 2018–2019 and 2020–2023 compared to 2015–2017 (p = 0.0256). The time to the first T315I-targeted approach was significantly reduced by year of mutation detection (p = 0.0002); the median time to T315I-targeted therapy over these periods was reduced from 17.8 to 2 months. Allogeneic hematopoietic stem cell transplantation was performed in 22 (25 %) of 88 patients: in 9 (41 %) – as the 1st T315I-targeted therapy; in 13 (59 %) patients, asciminib or ponatinib were used as bridge-therapy before it. Overall survival in the total group (n = 88) was 95; 79 and 68 % at 12; 36 and 60 months, respectively. The OS of patients with identified T315I mutation after 2020 was higher than in 2015–2017 and 2018–2019 periods, but the differences were not statistically significant (p = 0.1625).Conclusion. Selection of resistant clones with the T315I mutation can occur after any line of 1st–2nd generation TKI therapy. Improved availability of T315I-targeted therapy in Russia has been demonstrated depending on the period of T315I mutation detection. When the time to T315I-targeted therapy was reduced, a trend towards improved OS was observed. The differences in OS estimates identified may be related to selection factors given the retrospective nature of the study. Detailed prospective studies are required to evaluate the efficacy of different T315Idirected therapy protocols.

25 March 2026 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NVNikita Volkov
Nikita Volkov
IMIvan Moiseev
Ivan Moiseev
MKMaria Krivitskaya
Maria Krivitskaya
DZDmitrii Zhogolev
Dmitrii Zhogolev
MVMaria Vladovskaya
Maria Vladovskaya
AKAlexander Kulagin
Alexander Kulagin